Collaboration expanded to explore synthetically feasible chemical space
Enamine REAL database of synthetic compounds accessible via UCSF’s online ZINC platform.
Enamine, a chemical research organization and producer of novel building blocks and screening libraries, has expanded its collaboration on ZINC, a comprehensive online database of purchasable compounds curated by the Irwin and Shoichet laboratories in the Department of Pharmaceutical Chemistry at the University of California, San Francisco (UCSF). Via ZINC, Enamine will provide researchers at UCSF and the global drug-discovery community with access to the company’s REAL database, a unique database of more than 300 million novel synthetically feasible chemical structures as an efficient source of potential new compounds for a breadth of drug discovery projects.
The REAL database is the most significant contribution to currently purchasable chemical space, accounting for over 90% of all structures in ZINC. The compounds are conveniently selected in ZINC and then synthesized by Enamine in a single step from its building block stock, ensuring quick delivery and a high success rate.
Michael Bossert, Head of Strategic Alliances at Enamine said: “The number of compounds that Enamine can quickly access with its stock of 150,000 building blocks is astonishing. ZINC is a powerful platform that can efficiently support our endeavors to further expand our chemical space coverage to the global drug discovery community. We are pleased to see the researchers at UCSF benefitting from the diversity and novelty of our structures in the REAL compound arrays.”
John Irwin, Adjunct Professor at the UCSF School of Pharmacy and curator of ZINC agreed: “As we strive to bridge the gap between chemoinformatics and biology, the importance of working within a purchasable chemical space cannot be underestimated. We are pleased to continue our collaboration with Enamine in exploring ways to provide novel chemical compounds, designed and synthesized specifically for each research project, to the global biomedical community.”
Most compounds from the REAL database have already been successfully uploaded to ZINC. Over the last year, 92% of the more than 250 compounds ordered from Enamine have been delivered successfully to UCSF.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance